When InvestingPro's Fair Value models identified Integra LifeSciences (NASDAQ:IART) as significantly undervalued in September 2024, the healthcare company's stock was trading near its 52-week low. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback